Background Acute gout is an intensely painful, inflammatory arthritis. Although the non-steroidal anti-inflammatory drugs （NSAIDs） are widely used for this condition, the efficacy is based on only a few studies, par...Background Acute gout is an intensely painful, inflammatory arthritis. Although the non-steroidal anti-inflammatory drugs （NSAIDs） are widely used for this condition, the efficacy is based on only a few studies, particularly in China. We tried to assess the safety and efficacy of etoricoxib in the treatment of acute gouty arthritis in China. Methods A randomized, double-blind, active comparator study was conducted at 10 sites in China. Patients （n=178; 〉18 years of age） with acute gouty attack （〈48 hours） were treated for 5 days with etoricoxib （120 mg/d; n=89） or indometacin （75 mg twice daily; n=89）. The primary efficacy end point was self-assessed pain in the affected joint （0-4 point Likert scale） from days 2-5. Secondary end points included investigator assessments of tenderness and swelling, patient/ investigator global assessments of response to therapy, and patients discontinuing treatment. Safety was assessed by adverse events （AEs）. Results Etoricoxib and indometacin had comparable primary and secondary end points. Mean change difference from baseline from days 2-5 was 0.03 （95% confidence interval （CI） -0.19 to 0.25; P=0.6364）, which fell within the prespecifled comparative bounds of -0.5 to 0.5. No severe AEs were associated with etoricoxib use. Non-severe AEs were mainly digestive and general, and most （73.7%） were mild, although they caused withdrawal of two subjects in the etoricoxib group, due to bilateral renal calculi and uronephrosis of the left kidney （unrelated to etoricoxib） and fever and chills （potentially etoricoxib-related）. Overall, AEs were similar, although the absolute number of AEs in the etoricoxib group （n=31） was less than the indometacin group （n=34）. Conclusions Etoricoxib （120 mg once daily） is effective in treating acute gout, is generally safe and well-tolerated, and is comparable in efficacy to indometacin （75 mg twice daily）.展开更多
1例67岁男性患者,既往无高血压病史,因可疑痛风发作自2021年4月29日起口服依托考昔片(60 mg,qd)、碳酸氢钠片(1 g,tid),外用双氯芬酸钠二乙胺乳胶剂治疗。5月2日患者出现头晕,伴胸闷,自测血压180/90 mm Hg,服用苯磺酸氨氯地平片2.5 mg...1例67岁男性患者,既往无高血压病史,因可疑痛风发作自2021年4月29日起口服依托考昔片(60 mg,qd)、碳酸氢钠片(1 g,tid),外用双氯芬酸钠二乙胺乳胶剂治疗。5月2日患者出现头晕,伴胸闷,自测血压180/90 mm Hg,服用苯磺酸氨氯地平片2.5 mg后复测收缩压降至150 mm Hg,头晕、胸闷等症状较前改善。5月3日患者晨起再次出现头晕发作,自测血压204/101 mm Hg,就诊于急诊予以对症降压治疗后好转,嘱停用依托考昔片。5月4–7日患者血压波动于130~150/70~80 mm Hg,头晕间断发作,未服药治疗。5月8日患者晨起后再次出现头晕发作,自测血压190/90 mm Hg,加服苯磺酸氨氯地平片5 mg后就诊于心内科。入院经各项检查排除原发疾病影响,未予降压治疗,1 d后患者血压恢复正常,准予出院。展开更多
目的研究硫酸氨基葡萄糖联合依托考昔治疗膝关节骨性关节炎的疗效以及安全性。方法将2013年9月至2014年9月于我院骨科门诊确诊为膝关节骨性关节炎的150例患者按随机数字表法分成依托考昔组、硫酸氨基葡萄糖组和联合组,每组50例,分别给...目的研究硫酸氨基葡萄糖联合依托考昔治疗膝关节骨性关节炎的疗效以及安全性。方法将2013年9月至2014年9月于我院骨科门诊确诊为膝关节骨性关节炎的150例患者按随机数字表法分成依托考昔组、硫酸氨基葡萄糖组和联合组,每组50例,分别给予依托考昔、硫酸氨基葡萄糖、两种药物联合用药治疗6周。于用药2周和6周时采用西安大略和麦克马斯特大学(the Western Ontario and Mc Master Universities,WOMAC)骨关节炎指数评估疗效并观察不良反应。结果 11例因不良反应退出试验,6例失访,最终133例完成试验且随访资料完整,其中依托考昔组44例,硫酸氨基葡萄糖组43例,联合组46例。治疗2周后,依托考昔组和联合组的WOMAC指数较治疗前有显著改善,其中联合组的改善优于依托考昔组(P<0.05);依托考昔组、硫酸氨基葡萄糖组、联合组的不良反应例数分别为2例、1例和2例。治疗6周后,3组患者的WOMAC指数均优于治疗前(均P<0.05),其中联合组优于依托考昔组和硫酸氨基葡萄糖组(P<0.05),硫酸氨基葡萄糖组优于依托考昔组(P<0.05);3组各发生2例不良反应。结论硫酸氨基葡萄糖联合依托考昔治疗膝关节骨性关节炎比单独使用依托考昔或硫酸氨基葡萄糖的疗效好、起效快,值得临床推广。展开更多
文摘Background Acute gout is an intensely painful, inflammatory arthritis. Although the non-steroidal anti-inflammatory drugs （NSAIDs） are widely used for this condition, the efficacy is based on only a few studies, particularly in China. We tried to assess the safety and efficacy of etoricoxib in the treatment of acute gouty arthritis in China. Methods A randomized, double-blind, active comparator study was conducted at 10 sites in China. Patients （n=178; 〉18 years of age） with acute gouty attack （〈48 hours） were treated for 5 days with etoricoxib （120 mg/d; n=89） or indometacin （75 mg twice daily; n=89）. The primary efficacy end point was self-assessed pain in the affected joint （0-4 point Likert scale） from days 2-5. Secondary end points included investigator assessments of tenderness and swelling, patient/ investigator global assessments of response to therapy, and patients discontinuing treatment. Safety was assessed by adverse events （AEs）. Results Etoricoxib and indometacin had comparable primary and secondary end points. Mean change difference from baseline from days 2-5 was 0.03 （95% confidence interval （CI） -0.19 to 0.25; P=0.6364）, which fell within the prespecifled comparative bounds of -0.5 to 0.5. No severe AEs were associated with etoricoxib use. Non-severe AEs were mainly digestive and general, and most （73.7%） were mild, although they caused withdrawal of two subjects in the etoricoxib group, due to bilateral renal calculi and uronephrosis of the left kidney （unrelated to etoricoxib） and fever and chills （potentially etoricoxib-related）. Overall, AEs were similar, although the absolute number of AEs in the etoricoxib group （n=31） was less than the indometacin group （n=34）. Conclusions Etoricoxib （120 mg once daily） is effective in treating acute gout, is generally safe and well-tolerated, and is comparable in efficacy to indometacin （75 mg twice daily）.
文摘1例67岁男性患者,既往无高血压病史,因可疑痛风发作自2021年4月29日起口服依托考昔片(60 mg,qd)、碳酸氢钠片(1 g,tid),外用双氯芬酸钠二乙胺乳胶剂治疗。5月2日患者出现头晕,伴胸闷,自测血压180/90 mm Hg,服用苯磺酸氨氯地平片2.5 mg后复测收缩压降至150 mm Hg,头晕、胸闷等症状较前改善。5月3日患者晨起再次出现头晕发作,自测血压204/101 mm Hg,就诊于急诊予以对症降压治疗后好转,嘱停用依托考昔片。5月4–7日患者血压波动于130~150/70~80 mm Hg,头晕间断发作,未服药治疗。5月8日患者晨起后再次出现头晕发作,自测血压190/90 mm Hg,加服苯磺酸氨氯地平片5 mg后就诊于心内科。入院经各项检查排除原发疾病影响,未予降压治疗,1 d后患者血压恢复正常,准予出院。
文摘目的研究硫酸氨基葡萄糖联合依托考昔治疗膝关节骨性关节炎的疗效以及安全性。方法将2013年9月至2014年9月于我院骨科门诊确诊为膝关节骨性关节炎的150例患者按随机数字表法分成依托考昔组、硫酸氨基葡萄糖组和联合组,每组50例,分别给予依托考昔、硫酸氨基葡萄糖、两种药物联合用药治疗6周。于用药2周和6周时采用西安大略和麦克马斯特大学(the Western Ontario and Mc Master Universities,WOMAC)骨关节炎指数评估疗效并观察不良反应。结果 11例因不良反应退出试验,6例失访,最终133例完成试验且随访资料完整,其中依托考昔组44例,硫酸氨基葡萄糖组43例,联合组46例。治疗2周后,依托考昔组和联合组的WOMAC指数较治疗前有显著改善,其中联合组的改善优于依托考昔组(P<0.05);依托考昔组、硫酸氨基葡萄糖组、联合组的不良反应例数分别为2例、1例和2例。治疗6周后,3组患者的WOMAC指数均优于治疗前(均P<0.05),其中联合组优于依托考昔组和硫酸氨基葡萄糖组(P<0.05),硫酸氨基葡萄糖组优于依托考昔组(P<0.05);3组各发生2例不良反应。结论硫酸氨基葡萄糖联合依托考昔治疗膝关节骨性关节炎比单独使用依托考昔或硫酸氨基葡萄糖的疗效好、起效快,值得临床推广。
